

Catriona John Waitt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7245224/publications.pdf>

Version: 2024-02-01

44
papers

768
citations

567281

15
h-index

552781

26
g-index

44
all docs

44
docs citations

44
times ranked

949
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacovigilance in low- and middle-income countries: A review with particular focus on Africa. <i>British Journal of Clinical Pharmacology</i> , 2023, 89, 491-509.	2.4	31
2	Ethical issues in therapeutic use and research in pregnant and breastfeeding women. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 7-21.	2.4	28
3	Predicting Drug-Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling. <i>Clinical Pharmacokinetics</i> , 2022, 61, 375-386.	3.5	4
4	HIV viral load non-suppression and associated factors among pregnant and postpartum women in rural northeastern South Africa: a cross-sectional survey. <i>BMJ Open</i> , 2022, 12, e058347.	1.9	4
5	Stable warfarin dose prediction in sub-Saharan African patients: A machine learning approach and external validation of a clinical dose-initiation algorithm. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2022, 11, 20-29.	2.5	10
6	Twice neglected? Neglected diseases in neglected populations. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 367-373.	2.4	5
7	Bedaquiline exposure in pregnancy and breastfeeding in women with rifampicin-resistant tuberculosis. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3548-3558.	2.4	8
8	Optimizing Pharmacology Studies in Pregnant and Lactating Women Using Lessons From HIV: A Consensus Statement. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 36-48.	4.7	29
9	Developing and Validating a Clinical Warfarin Dose-Initiation Model for Black African Patients in South Africa and Uganda. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1564-1574.	4.7	8
10	Anticoagulation in sub-Saharan Africa: Are direct oral anticoagulants the answer? A review of lessons learnt from warfarin. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3699-3705.	2.4	12
11	Anti-Infective Dosing in Special Populations: Pregnancy. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 977-986.	4.7	10
12	Improving anticoagulation in sub-Saharan Africa: What are the challenges and how can we overcome them?. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3056-3068.	2.4	13
13	Advancing knowledge in perinatal HIV treatment. <i>Lancet HIV</i> , 2021, 8, e124-e125.	4.7	1
14	Infant Exposure to Dolutegravir Through Placental and Breast Milk Transfer: A Population Pharmacokinetic Analysis of DolPHIN-1. <i>Clinical Infectious Diseases</i> , 2021, 73, e1200-e1207.	5.8	11
15	Validation of a UHPLC-MS/MS Method to Quantify Twelve Antiretroviral Drugs within Peripheral Blood Mononuclear Cells from People Living with HIV. <i>Pharmaceuticals</i> , 2021, 14, 12.	3.8	7
16	An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR). <i>Trials</i> , 2021, 22, 831.	1.6	2
17	Engendering health systems in response to national rollout of dolutegravir-based regimens among women of childbearing potential: a qualitative study with stakeholders in South Africa and Uganda. <i>BMC Health Services Research</i> , 2020, 20, 705.	2.2	10
18	Community acceptability of dolutegravir-based HIV treatment in women: a qualitative study in South Africa and Uganda. <i>BMC Public Health</i> , 2020, 20, 1883.	2.9	9

#	ARTICLE	IF	CITATIONS
19	Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1772-1777.	3.0	69
20	Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial. <i>Lancet HIV</i> , 2020, 7, e332-e339.	4.7	75
21	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. <i>PLoS ONE</i> , 2020, 15, e0227458.	2.5	25
22	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0
23	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0
24	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0
25	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0
26	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0
27	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0
28	Inclusion of pregnant women in antiretroviral drug research: what is needed to move forwards?. <i>Journal of the International AIDS Society</i> , 2019, 22, e25372.	3.0	15
29	Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study). <i>PLoS Medicine</i> , 2019, 16, e1002895.	8.4	58
30	Reply to Banda et al., "Interpretation of Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine". <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	1
31	Transmission of CMV, HTLV-1, and HIV through breastmilk. <i>The Lancet Child and Adolescent Health</i> , 2019, 3, 264-273.	5.6	43
32	Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokinetics. <i>Pharmacogenomics</i> , 2019, 20, 217-223.	1.3	4
33	Pharmacokinetics of maraviroc in plasma and breastmilk in a treatment-experienced perinatally HIV-1-infected woman. <i>Aids</i> , 2019, 33, 2443-2444.	2.2	0
34	Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	16
35	Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African mother-infant pairs. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1013-1019.	3.0	30
36	Validation and clinical application of a novel LC-MS method for quantification of dolutegravir in breast milk. <i>Bioanalysis</i> , 2018, 10, 1933-1945.	1.5	3

#	ARTICLE	IF	CITATIONS
37	Does U=U for breastfeeding mothers and infants? Breastfeeding by mothers on effective treatment for HIV infection in high-income settings. <i>Lancet HIV</i> , 2018, 5, e531-e536.	4.7	52
38	High prevalence and long duration of nervous system and psychiatric adverse drug reactions in Ugandan patients taking efavirenz 600 mg daily. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3158-3161.	3.0	8
39	Development, validation and clinical application of a method for the simultaneous quantification of lamivudine, emtricitabine and tenofovir in dried blood and dried breast milk spots using LC-MS/MS. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1060, 300-307.	2.3	23
40	Spontaneous adverse drug reaction reports for neonates and infants in the UK 2001-2010: content and utility analysis. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1601-1612.	2.4	17
41	Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2816-2822.	3.0	21
42	Is infant exposure to antiretroviral drugs during breastfeeding quantitatively important? A systematic review and meta-analysis of pharmacokinetic studies. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1928-1941.	3.0	39
43	Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study. <i>Clinical Infectious Diseases</i> , 2015, 61, 453-463.	5.8	32
44	Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 555-561.	3.0	35